| Identification | Back Directory | [Name]
Sifalimumab | [CAS]
1006877-41-3 | [Synonyms]
Sifalimumab
Sifalimumab (anti-IFNa1)
Research Grade Sifalimumab(DHB94501) |
| Hazard Information | Back Directory | [Uses]
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research[1][2]. | [in vivo]
Sifalimumab (subcutaneous injection; 30 mg/kg and 3 μg/g) treatment shows therapeutic effect and attenuates the lymphocyte infiltration[2]. | Animal Model: | Wild-type male BALB/c mice[2] | | Dosage: | 30 mg/kg and 3 μg/g | | Administration: | Subcutaneous injection; 30 mg/kg and 3 μg/g | | Result: | Prevented the increase CpG-induced, decreasing CD86 fluorescence intensity by 1.9-fold (P < 0.05).
Showed a potentially therapeutic effect attenuating the CpG-induced lymphocyte infiltration.
Attenuated the CD45 increase (P<0.05).
|
| [References]
[1] Merrill JT, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov;70(11):1905-13. DOI:10.1136/ard.2010.144485
[2] La Maestra S, et al. Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation. Drug Deliv Transl Res. 2018 Oct;8(5):1345-1354. DOI:10.1007/s13346-018-0535-3 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|